Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11358487 | 0.81 | CYP2A6 (0.41) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL11891561 | 0.80 | MAPT (0.38) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL2221239 | 0.76 | PTPN22 (0.54) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL1096216 | 0.74 | TSHR (0.56) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL2873053 | 0.74 | CYP2A6 (0.56) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL4124570 | 0.74 | HSD17B10 (0.46) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL8050013 | 0.73 | HSD17B10 (0.50) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL30367845 | 0.73 | HSD17B10 (0.50) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL15910482 | 0.72 | HSD17B10 (0.44) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 | |
| SCHEMBL15853168 | 0.72 | ALDH1A1 (0.44) | HSD17B10ALDH1A1CYP2A6TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165811-A1 | METHOD FOR TREATING SYMPTOMS OF VIRAL INFECTIONS | WAINER IRVING W (US) | 2023-06-01 | — | — | US | disclosed |
| US-20180141894-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180117574-A1 | BIARYL LIGANDS FOR TRANSITION METAL-CATALYZED REACTIONS | UNIV CALIFORNIA (US) | 2018-05-03 | — | — | US | disclosed |
| US-9908841-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170173569-A1 | Fe-ppm Pd, Cu and/or Ni Nanoparticle-Catalyzed Reactions in Water | LIPSHUTZ BRUCE H (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170081276-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170007556-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-12 | — | — | US | disclosed |
| US-9522871-B2 | Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160331702-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2016-11-17 | — | — | US | disclosed |
| US-9492405-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160009636-A9 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-01-14 | — | — | US | disclosed |
| US-20150157580-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-06-11 | — | — | US | disclosed |
| US-20140187645-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | SRI INTERNATIONAL | 2013-01-03 | — | — | US | disclosed |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | Services, National Institutes of Health | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141894-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | HSD17B10 2488/4885ALDH1A1 2747/4885CYP2A6 1173/4885 |
| US-20160009636-A9 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | HSD17B10 2488/4885ALDH1A1 2747/4885CYP2A6 1173/4885 |
| US-20150157580-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | CNR1, CNR2, GPR68 | HSD17B10 1442/4885ALDH1A1 3019/4885CYP2A6 665/4885 |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | HSD17B10 2525/4885ALDH1A1 2039/4885CYP2A6 1306/4885 |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | HSD17B10 2488/4885ALDH1A1 2747/4885CYP2A6 1173/4885 |
| US-20170081276-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | HSD17B10 2488/4885ALDH1A1 2747/4885CYP2A6 1173/4885 |
| US-20170173569-A1 | Fe-ppm Pd, Cu and/or Ni Nanoparticle-Catalyzed Reactions in Water | TPR, SOD1, ZNF207 | HSD17B10 4667/4885ALDH1A1 1764/4885CYP2A6 4727/4885 |
| US-20180117574-A1 | BIARYL LIGANDS FOR TRANSITION METAL-CATALYZED REACTIONS | EPHA2, L1CAM, ERBB2 | HSD17B10 3523/4885ALDH1A1 801/4885CYP2A6 226/4885 |
| US-20140187645-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | HSD17B10 2488/4885ALDH1A1 2747/4885CYP2A6 1173/4885 |
| US-20160331702-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | CNR1, CNR2, GPR68 | HSD17B10 1442/4885ALDH1A1 3019/4885CYP2A6 665/4885 |
| US-20170007556-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | HSD17B10 2661/4885ALDH1A1 2122/4885CYP2A6 1494/4885 |
| US-20230165811-A1 | METHOD FOR TREATING SYMPTOMS OF VIRAL INFECTIONS | ACE, CCL11, CRH | HSD17B10 1406/4885ALDH1A1 3897/4885CYP2A6 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.